| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Here's a roundup of top developments in the biotech space over the last 24 hours.
(Biotech stocks hitting 52-week highs on Dec. 10)
(Biotech stocks hitting 52-week lows on Dec. 10)
Correvio Pharma Corp (NASDAQ:CORV) said FDA's Cardiovascular and Renal Advisory Committee, which reviewed its Brinavess, voted that the benefit-risk profile was not adequate to support approval, with two staffers voting for the drug and 11 against.
The FDA has set a PDUFA action date of Dec. 24 for approving the drug.
The stock tumbled 57.14% to 60 cents in after-hours trading.
Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced positive top-line results from the in-clinic part of a Phase 2 study of its developmental ready-to-use, or RTU, glucagon in patients who experienced post prandial hypoglycemic episodes following bariatric surgery.
The study showed that of patients with a successful meal challenge, all subjects were able to self-administer a mini dose of study drug, as directed, during the setting of declining blood glucose. A mini dose of RTU glucagon was sufficient to restore or maintain normal blood glucose level within 15 minutes of administration. The incidence of follow-on episode of hypoglycemia was less with a mini dose of RTU glucagon compared to placebo.
"Mini doses of RTU glucagon appear safe and well tolerated, and no serious adverse events occurred," the company added.
The stock climbed 11% to $9.99 in after-hours trading.
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) presented data from the open-label, dose-escalation Phase 3 study of Trans Sodium Crocetinate, or TSC, plus standard of care, or SOC, that showed that the investigational compound increased survival in inoperable glioblastoma multiforme patients. The findings were presented at the inaugural Glioblastoma Drug Development Summit in Boston.
In the 19-patient study, safety was demonstrated in all patients receiving TSC at all dosing levels.
The stock jumped 26.85% to 55 cents in after-hours trading.
See also: 5 Stocks Moving On ASH Presentations
Novartis AG (NYSE:NVS) said the FDA has accepted its sBLA for Xolair for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids. The PDUFA date is likely to be by the third quarter of 2020. Xolair has already been approved for treating moderate-to-severe or severe persistent asthma in over 90 countries.
Flexion said Neil Bodick, its chief scientific officer and co-founder, will retire, effective Jan. 3, 2020. Following his resignation, Bodick will continue in a consulting role, as part of the transition of his responsibilities.
The stock added 3.87% to $21.76 in after-hours trading.
Iterum Therapeutics PLC (NASDAQ:ITRM) said its SURE 3 clinical trial that evaluated its sulopenem compared to ertapenem in complicated intra-abdominal infections did not meet the primary end point of clinical response on Day 28 in the micro-NITT population.
The difference in outcomes was 4.7% with a 95% confidence interval on that differences of -10.3% to 1%. The company noted that non-inferiority required that the lower limit of the difference in the outcome rates to be more than or equal to -10%.
The stock plummeted 40.21% to $2.90 in after-hours trading.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) said it has successfully advanced to the next higher dose in the ongoing Phase 1 multiple ascending dose, or MAD, study of CRV431.
"The data generated from this trial is expected to guide further development of CRV431 for the treatment of NASH, with plans to initiate Phase 2 clinical studies in the first half of 2020," the company said.
The stock gained 4.52% to $5.78 in after-hours trading.
Aquestive Therapeutics Inc (NASDAQ:AQST) said it intends to sell $35 million worth of shares of its common stock in an underwritten public offering. All shares are being sold by the company. It intends to use the net proceeds for the commercial launch of Sympazan, among other things.
The stock slipped 15.45% to $6.35 in after-hours trading.
Orthopediatrics Corp (NASDAQ:KIDS) said it is commencing an underwritten public offering of its common stock. The offering will also include shares offered by certain selling shareholders, the proceeds of which will no be received by the company.
The stock moved down 7.86% to $35.54 in after-hours trading.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) said it has priced an underwritten public offering of 3.82 million shares at $22.25 apiece. The company expects to raise gross proceeds of $84.995 million from the offering. The offering is expected to close on or about Dec. 13.
The stock declined 5.41% to $22.92 in after-hours trading.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) said it has commenced an underwritten registered public offering of $200 million worth of its shares. All the shares are being offered by the company.
The stock fell 3.43% to $17.45 in after-hours trading.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) said it has priced its previously-announced underwritten secondary offering of 1.2 million shares by investment funds affiliated with Bay Capital at $107.85 per share. The offering is set to close on or about Dec. 13. The company said it will not receive any proceeds from the offering.
The stock retreated 7.17% to $110 in after-hours trading.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) said it intends to offer shares of its common stock in an underwritten public offering. All the shares are to be sold by Marinus. Concurrent with the offering, the company also plans to sell in a private placement, a number of convertible preferred shares, equal to an aggregate purchase price of up to approximately $30 million at the price of the common stock offering.
The stock dipped 10.08% to $1.16 in after-hours trading.
MacroGenics Inc (NASDAQ:MGNX) and Zai Lab Ltd (NASDAQ:ZLAB) – oral presentation of detailed results from the second interim overall survival analysis form the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have been previously treated with anti-HER2-targeted therapies
Seattle Genetics, Inc. (NASDAQ:SGEN) – already-released Phase 2 data for Tucatinib ONT-380 in combination with Roche Holdings AG Basel ADR (OTC:RHHBY) Herceptin and oral chemotherapy Xeloda in HER2+ metastatic breast cancer
G1 Therapeutics Inc (NASDAQ:GTHX) – additional Phase 1b data for Lerociclib plus AstraZeneca plc (NYSE:AZN)'s Faslodex in ER+ breast cancer
Posted In: ACHV AIMT AQST ARGX ARQL ARVN AUPH AVDL AXSM AZN BBIO BHC BMY BOLD CABA CKPT CNSP CORV DCPH DFFN
